Quest Diagnostics
826 hedge funds and large institutions have $13.7B invested in Quest Diagnostics in 2023 Q4 according to their latest regulatory filings, with 108 funds opening new positions, 253 increasing their positions, 330 reducing their positions, and 64 closing their positions.
125% more call options, than puts
Call options by funds: $176M | Put options by funds: $78.3M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
69% more first-time investments, than exits
New positions opened: 108 | Existing positions closed: 64
14% more capital invested
Capital invested by funds: $12B → $13.7B (+$1.7B)
4% more funds holding
Funds holding: 794 → 826 (+32)
0.8% more ownership
Funds ownership: 87.73% → 88.54% (+0.8%)
23% less repeat investments, than reductions
Existing positions increased: 253 | Existing positions reduced: 330
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$276M |
| 2 |
DSA
Davis Selected Advisers
Tucson,
Arizona
|
+$131M |
| 3 |
NI
Nuance Investments
Kansas City,
Missouri
|
+$79.2M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$52.1M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$49.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$106M |
| 2 |
LSV Asset Management
Chicago,
Illinois
|
-$79.6M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
-$53.8M |
| 4 |
Nordea Investment Management
Stockholm,
Sweden
|
-$50.7M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$34.1M |
DGX Hedge Fund Activity: Q4 2023 in Review
826 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q4 2023, worth a combined $13.7B — up 14% from $12B a quarter earlier.
Buyers outnumbered sellers: 108 funds opened new DGX positions and 64 closed out — a net gain of 44 holders — while 253 added to existing stakes and 330 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $276M. The largest seller was BlackRock, cutting an estimated $106M.
- 826 institutional investors held Quest Diagnostics (DGX) as of Q4 2023, up from 794 in Q3 2023.
- Funds reported $13.7B of Quest Diagnostics stock for Q4 2023, up 14% quarter-over-quarter.
- 108 funds opened new Quest Diagnostics positions in Q4 2023 and 64 closed out, a net change of +44 holders.
- The largest Quest Diagnostics buyer in Q4 2023 was Morgan Stanley, an estimated $276M added.
- The largest Quest Diagnostics seller in Q4 2023 was BlackRock, an estimated $106M sold.
Based on aggregated 13F filings for Q4 2023.